MARKET

SCYX

SCYX

SCYNEXIS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.570
-0.120
-2.56%
Closed 16:00 09/25 EDT
OPEN
4.690
PREV CLOSE
4.690
HIGH
4.880
LOW
4.480
VOLUME
71.42K
TURNOVER
--
52 WEEK HIGH
14.40
52 WEEK LOW
4.450
MARKET CAP
48.45M
P/E (TTM)
-0.0919
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 8h ago
Mixed shelf roundup - healthcare
The following healthcare companies have filed for mixed shelf offerings:Citius Pharmaceuticals (CTXR): $100M.Flexion Therapeutics (FLXN): $300M.SCYNEXIS (SCYX): $200M.Kezar Life Sciences (KZR): $200M.
Seekingalpha · 09/11 20:41
SCYNEXIS to Participate in H.C. Wainwright Conference and Maxims Antifungal Webinar
JERSEY CITY, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Dr. Marco Taglietti, Chief Executive Officer, will participate in
GlobeNewswire · 09/10 13:38
SCYNEXIS Highlights Presentations On Ibrexafungerp's Potential For Treatment Of Vulvovaginal Candidiasis At Infectious Diseases Society for Obstetrics and Gynecology Meeting
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of two oral abstracts and a
Benzinga · 08/13 12:19
SCYNEXIS Reports Second Quarter 2020 Financial Results and Provides Company Update
In July, SCYNEXIS announced that it had successfully conducted pre-NDA meetings with the FDA regarding ibrexafungerp for the treatment of Vulvovaginal Candidiasis (VVC) more commonly known as vaginal yeast infection. NDA submission for this indication remains
GlobeNewswire · 08/10 12:20
SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis
* Following recent productive meetings, the Company remains on track to submit a New Drug Application (NDA) for the treatment of Vulvovaginal Candidiasis (VVC), also known as Vaginal Yeast Infection, in Q4 2020.JERSEY CITY, N.J., July 29, 2020 (GLOBE NEWSWIRE)
GlobeNewswire · 07/29 12:00
SCYNEXIS Announces Four Posters Presented At ASM Microbe 2020 Highlighting Potential Clinical Utility Of Ibrexafungerp
JERSEY CITY, N.J., July 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today
Benzinga · 07/22 12:02
SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp
Clinical and preclinical studies demonstrate ibrexafungerp’s broad-spectrum activity and potential to treat a range of serious and life-threatening fungal infectionsJERSEY CITY, N.J., July 22, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechno
GlobeNewswire · 07/22 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SCYX. Analyze the recent business situations of SCYNEXIS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SCYX stock price target is 45.14 with a high estimate of 100.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 62
Institutional Holdings: 13.28M
% Owned: 125.25%
Shares Outstanding: 10.60M
TypeInstitutionsShares
Increased
14
423.84K
New
14
46.76K
Decreased
8
54.86K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.04%
Pharmaceuticals & Medical Research
+1.34%
Key Executives
Chairman/Director
Pamela Kirby
President/Chief Executive Officer/Director
Marco Taglietti
Chief Financial Officer
Eric Francois
Vice President/Director of Sales/Director of Marketing
Jim Maffezzoli
Vice President
Nkechi Azie
General Counsel
Scott Sukenick
Other
David Angulo
Director
Armando Anido
Director
Laurent Arthaud
Director
Steven Gilman
Director
Ann Hanham
Director
David Hastings
Director
Patrick Langlois
Director
Clarence Machado
Director
Guy Macdonald
Director
Jean-Yves Nothias
Director
Philippe Tinmouth
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SCYX
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of SCYNEXIS Inc stock information, including NASDAQ:SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.